DiscoveryProbe™ FDA-approved Drug Library: Atomic Evidence for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 clinically validated compounds, each approved by major regulatory agencies or listed in authoritative pharmacopeias (ApexBio product page). The library is provided as 10 mM DMSO solutions, supporting high-throughput screening (HTS) and high-content screening (HCS) workflows (L1021 datasheet). It enables rapid drug repositioning and pharmacological target identification, including for emerging pathogens such as SARS-CoV-2 (Andi et al., 2022). Mechanistically, compounds span receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and pathway regulators. The resource supports robust experimental reproducibility, with solution stability validated up to 24 months at -80°C (ApexBio L1021 documentation).

Biological Rationale

The reuse of clinically approved drugs for new indications, known as drug repositioning, is a proven strategy to accelerate therapeutic development (Andi et al., 2022). Regulatory-approved compounds have established safety profiles and pharmacokinetics. This allows rapid progression from bench to clinic, minimizing the risks and costs associated with de novo drug discovery. The DiscoveryProbe™ FDA-approved Drug Library systematically aggregates such compounds across disease areas including cancer, neurodegeneration, and infectious diseases (internal summary). The biological rationale is supported by recent pandemic responses, where repurposed antivirals like remdesivir, originally designed for hepatitis C, were rapidly evaluated and deployed for COVID-19 (Andi et al., 2022).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library contains compounds with well-characterized mechanisms, including:

• Receptor agonists/antagonists: Block or activate cellular signaling, e.g., beta-blockers and opioid agonists.
• Enzyme inhibitors: Interfere with enzymatic activity (e.g., kinase inhibitors, protease inhibitors).
• Ion channel modulators: Alter excitability or conductance (e.g., calcium channel blockers).
• Signal pathway regulators: Modulate key intracellular cascades (e.g., mTOR, MAPK).

Each compound's mechanism is curated from clinical dossiers and peer-reviewed studies. For example, doxorubicin inhibits topoisomerase II, metformin activates AMP-activated protein kinase (AMPK), and atorvastatin inhibits HMG-CoA reductase (ApexBio). The diversity of mechanisms enables broad interrogation of disease biology and target validation in HTS/HCS formats.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library comprises 2,320 compounds, each with regulatory approval by the FDA, EMA, HMA, CFDA, or PMDA, or listing in major pharmacopeias (ApexBio).
• Compounds are delivered as 10 mM DMSO solutions, compatible with automated HTS/HCS workflows (internal article).
• Compound solutions are stable for 12 months at -20°C and up to 24 months at -80°C, as verified by LC-MS and HPLC (ApexBio documentation).
• Benchmark studies have identified clinically approved hepatitis C virus NS3/4A inhibitors (e.g., boceprevir, telaprevir) as covalent binders of SARS-CoV-2 main protease (Mpro), validating the drug repositioning approach (Andi et al., 2022).
• Remdesivir, an FDA-approved antiviral originally for hepatitis C/Ebola, was rapidly repurposed for COVID-19 via screening of regulatory-approved compound libraries (Andi et al., 2022).
• The resource supports screening for enzyme inhibitors, with successful applications in cancer and neurodegenerative disease models (internal article).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for:

• High-throughput screening (HTS) in 96-well or deep-well microplate formats.
• High-content screening (HCS) using automated imaging systems.
• Drug repositioning campaigns to identify new indications for existing drugs.
• Pharmacological target identification in disease models, including cancer and neurodegeneration.
• Pathway mapping and mechanistic studies leveraging known compound activities.

This article extends the discussion in "DiscoveryProbe™ FDA-approved Drug Library: Transforming Enzyme Inhibitor Screening" by detailing evidence for diverse mechanistic classes and benchmarking stability, while updating use-case guidance for signal pathway regulation.

Compared to "DiscoveryProbe FDA-approved Drug Library: Accelerating HTS/HCS Workflows", this article clarifies quantitative solution stability and regulatory scope for translational applications.

Common Pitfalls or Misconceptions

• The library is not a substitute for clinical validation: Hits identified in vitro require in vivo confirmation and clinical trials.
• Not all compounds are effective in every disease model: Efficacy and toxicity are context-dependent.
• Compound solubility and stability must be verified under assay-specific conditions: Precipitation or degradation may occur outside recommended storage/use parameters.
• Mechanisms of action are not always fully understood for every compound: Some entries have incomplete mechanistic annotation.
• Cross-reactivity and off-target effects may confound results: Validation with orthogonal assays is recommended.

Workflow Integration & Parameters

The L1021 kit is provided as pre-dissolved 10 mM DMSO solutions in a selection of vessel formats: 96-well microplates, deep-well plates, or 2D barcoded screw-top tubes (ApexBio). Solutions are shipped on blue ice for evaluation samples and at room temperature or on blue ice for bulk formats. Upon receipt, compounds should be stored at -20°C (for up to 12 months) or -80°C (for up to 24 months) to ensure chemical integrity. Integration into automated liquid handling systems is supported by the plate and tube formats (internal article). Each well includes a unique compound identifier for reproducible screening and data traceability. QC analysis is documented for each lot, including LC-MS and HPLC profiles. Users are advised to equilibrate compounds to room temperature before use to minimize DMSO precipitation. For HTS/HCS, the recommended assay concentration range is 0.1–10 μM, but optimal conditions depend on the specific assay and target biology.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated, high-density resource for HTS, HCS, and drug repositioning. It aggregates regulatory-approved compounds with diverse mechanisms, enabling robust pharmacological discovery and translational research. Benchmark evidence underscores its utility in rapid response to emerging diseases and in fundamental pathway elucidation. Researchers can leverage this resource to accelerate target identification, optimize screening workflows, and improve the reproducibility of preclinical pharmacology. For further details and ordering information, visit the DiscoveryProbe™ FDA-approved Drug Library product page.